13048_2019_591_MOESM1_ESM.docx (20.55 kB)
MOESM1 of Development and validation of circulating CA125 prediction models in postmenopausal women
journal contribution
posted on 2019-11-27, 04:36 authored by Naoko Sasamoto, Ana Babic, Bernard Rosner, Renée Fortner, Allison Vitonis, Hidemi Yamamoto, Raina Fichorova, Linda Titus, Anne Tjønneland, Louise Hansen, Marina Kvaskoff, Agnès Fournier, Francesca Mancini, Heiner Boeing, Antonia Trichopoulou, Eleni Peppa, Anna Karakatsani, Domenico Palli, Sara Grioni, Amalia Mattiello, Rosario Tumino, Valentina Fiano, N. Onland-Moret, Elisabete Weiderpass, Inger Gram, J. Quirós, Leila Lujan-Barroso, Maria-Jose Sánchez, Sandra Colorado-Yohar, Aurelio Barricarte, Pilar Amiano, Annika Idahl, Eva Lundin, Hanna Sartor, Kay-Tee Khaw, Timothy Key, David Muller, Elio Riboli, Marc Gunter, Laure Dossus, Britton Trabert, Nicolas Wentzensen, Rudolf Kaaks, Daniel Cramer, Shelley Tworoger, Kathryn TerryAdditional file 1: Table S1. Baseline characteristics across Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), European Prospective Investigation into Cancer and Nutrition (EPIC), Nurses’ Health Studies (NHS/NHSII), and New England Case-Control Study (NEC).Table S2. Age-adjusted association between predictors and CA125 levels above 35 U/mL in Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO).